Progress in the development of cell therapies for the treatment of a range of diseases is accelerating, helped along by advancements in gene editing and manufacturing techniques. Pharmaceutical company AstraZeneca has been investing heavily in cell therapy technologies for the treatment of cancer, particularly solid tumors that pose distinct challenges, and is looking to make contributions to patient care.

In this podcast from the Science custom publishing office and funded by Astrazeneca, Senior Editor Erika Berg interviews Mark Cobbold, Senior Vice President of Discovery and the Head of Oncology Cell Therapy at AstraZeneca. They explore the future of cell therapy in cancer treatment, the science behind "living medicines," and the vision of scalable, off-the-shelf cell therapies. This episode is a must-listen for anyone passionate about the future of oncology and personalized medicine.